✦ LIBER ✦

Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, pharmacokinetic (PK), and biolo

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 139 KB

A phase I dose escalation study of epide

✍ Karp, D.D; Ferrante, K.J; Tensfeldt, T.G; Thurer, R.L; LoCicero, J; Huberman, M. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

552 Evaluation of the pharmacokinetic (P

✍ C. Delbaldo; J.Y. Pierga; V. Dieras; S. Faivre; M. Bonnay; J.C. Vedovato; M. Mue 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

ZD1839 (‘Iressa’), an orally-active, sel

✍ G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 338 KB

Phase I dose-finding and pharmacokinetic

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

Pilot trial of ZD1839 (IressaTM), an ora

✍ Laurie, S.A; Miller, V.A; Johnson, D; Ng, K.K; Heelan, R.T; Pizzo, B.A; Perez, W 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB